منابع مشابه
Rhenium 188: The Poor Man's Yttrium
After the landmark, IAEA trial confirming the potential of intra-arterially used Re 188 Lipoidol for the treatment of inoperable hepatocellular carcinoma (HCC), it was surprising to note that none of the participating centers took this work forward. To a nonnuclear physician or scientist, it would seem baffling, but we in NM are well aware of the difficulties in instituting a new radionuclide t...
متن کاملRhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy
Rhenium-188 (Re-188) is a high energy β-emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy γ-emission, which could be detected by γ-cameras, for imaging, biodi...
متن کاملMonoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
Rhenium-188, obtained from an alumina-based tungsten-188/rhenium-188 generator, is actually considered a useful candidate for labeling biomolecules such as antibodies, antibody fragments, peptides, and DNAs for radiotherapy. There is a widespread interest in the availability of labeling procedures that allow obtaining 188Re-labeled radiopharmaceuticals for various therapeutic applications, in p...
متن کاملFeasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
BACKGROUND This paper describes the feasibility of intra-arterial high-activity administration of (188)Re-microspheres. METHODS Patients with unresectable colorectal liver metastases or hepatocellular cancer (HCC) received single treatments with (188)Re-microspheres. The administered activity was calculated to give a liver dose of 100 Gy. From post-therapeutic scans and urine sampling, the do...
متن کاملSafety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma
There is a need for effective "broad spectrum" therapies for metastatic melanoma which would be suitable for all patients. The objectives of Phase Ia/Ib studies were to evaluate the safety, pharmacokinetics, dosimetry, and antitumor activity of (188)Re-6D2, a 188-Rhenium-labeled antibody to melanin. Stage IIIC/IV metastatic melanoma (MM) patients who failed standard therapies were enrolled in b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Nuclear Medicine
سال: 2017
ISSN: 1450-1147
DOI: 10.4103/1450-1147.198225